Treatment of hypoparathyroidism using triphenyl calcilytic compounds
AssigneesCalcilytix Therapeutics, Inc., The United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsMary Scott ROBERTS, Michael T. COLLINS, Rachel I. GAFNI, Iris R. HARTLEY, Kelly B. L. ROSZKO
Life of this patent
Estimating the term…
Abstract
The present disclosure provides a method of treating hypoparathyroidism, such as hypoparathyroidism associated with a prior surgical procedure (e.g., a post-surgical hypoparathyroidism (PSH)), in a subject in need thereof, with a therapeutically effective amount of a compound of formula (I), in particular CLTX-305. In particular, a therapeutically effective amount of the compound of formula (I) (e.g., CLTX-305) reduces symptoms associated with hypoparathyroidism and minimizes hypercalciuria in hypoparathyroidism (e.g., PSH) subjects.
Claims45
A method of treating a hypoparathyroidism in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound represented by formula (I):
- or a solvate, a hydrate, a pharmaceutically acceptable salt, or a combination thereof.
Dependencies are inferred from the claim text.